Skip to content
YCS22· Other

Guardian Bio

Dendritic cell-based platform for cancer therapy

ActiveChecked 18h ago
Batch
S22
Status, per YC
Active
Team size
2
HQ
Boston, MA
In S22233 companies, 55% AI
guardian-bio.comYC profile

Founders

Not read from YC yet; the weekly run fills these in.

Same space

About Guardian Bio

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

Boston, MA, USA

Guardian Bio: questions

Which YC batch was Guardian Bio in?

Guardian Bio was in Y Combinator's Summer 2022 batch (S22).

Is Guardian Bio still active?

Y Combinator lists Guardian Bio as active.

Where is Guardian Bio based?

Guardian Bio lists Boston, MA, USA as its location on YC's directory.

Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.

Weekly: new YC data, AI and devtools companies and status changes, Mondays.